Cargando…

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial

BACKGROUND: Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). METHODS: Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vizza, Carmine Dario, Jansa, Pavel, Teal, Simon, Dombi, Theresa, Zhou, Duo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586020/ https://www.ncbi.nlm.nih.gov/pubmed/28874133 http://dx.doi.org/10.1186/s12872-017-0674-3

Ejemplares similares

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN)
por: Vijay Kumar, J.R., et al.
Publicado: (2021)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility
por: Adnan, Mudasser, et al.
Publicado: (2021)

Sildenafil and Bosentan Plasma Concentrations in a Human Immunodeficiency Virus- Infected Patient with Pulmonary Arterial Hypertension Treated with Ritonavir-Boosted Protease Inhibitor
por: Chinello, Pierangelo, et al.
Publicado: (2015)

Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014)

Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
por: Berger, Rolf M. F., et al.
Publicado: (2017)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Sildenafil in pediatric pulmonary arterial hypertension
por: Dhariwal, AK, et al.
Publicado: (2015)

Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study
por: Berger, Ariel, et al.
Publicado: (2012)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension
por: Liao, Shutan, et al.
Publicado: (2019)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Sildenafil in the treatment of pulmonary hypertension
por: Barnett, Christopher F, et al.
Publicado: (2006)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension
por: Lee, Dong Seok, et al.
Publicado: (2010)

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
por: Ramani, Gautam V, et al.
Publicado: (2010)

Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
por: Lilyasari, Oktavia, et al.
Publicado: (2019)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
por: Tang, Yi, et al.
Publicado: (2022)

Case Report: Bosentan and Sildenafil Exposure in Human Milk - A Contribution From the ConcePTION Project
por: Nauwelaerts, Nina, et al.
Publicado: (2022)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Badagliacca, Roberto, et al.
Publicado: (2021)

Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report
por: Omarjee, Loukman, et al.
Publicado: (2017)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rjgpb1qrkicvirocu878hbff2o